PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-15.16%
Negative net income growth while AVXL stands at 8.04%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
8.11%
D&A growth of 8.11% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
14.88%
Deferred tax of 14.88% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
33.33%
SBC growth while AVXL is negative at -47.20%. John Neff would see competitor possibly controlling share issuance more tightly.
-359.86%
Both reduce yoy usage, with AVXL at -179.76%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-185.03%
Both reduce yoy usage, with AVXL at -211.41%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-14.88%
Both negative yoy, with AVXL at -97.32%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-25.31%
Both yoy CFO lines are negative, with AVXL at -54.66%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-2962.50%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2962.50%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
56.30%
Debt repayment growth of 56.30% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
23135.79%
Stock issuance far above AVXL's 61.25%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
100.00%
Buyback growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.